Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nimodipine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Nimodipine | DRUG | - |
Please contact site for information.
Nimodipine is being studied for use in cocaine-related disorders. It is an investigational small molecule in Phase 1 clinical development for this indication. The drug is being evaluated in a completed Phase 1 trial in the United States, though the trial was uncontrolled and not randomized or double-blinded.
Nimodipine is being developed by National Healthcare Corp. (NHC). The company is conducting clinical research on the drug for cocaine-related disorders. Nimodipine is currently in Phase 1 development, with one completed clinical trial registered under NCT00000280.
Nimodipine is in Phase 1 clinical development for cocaine-related disorders. It is an investigational drug, not yet approved by regulatory authorities. The Phase 1 trial, NCT00000280, has been completed, and the drug remains in early-stage clinical research.
Nimodipine has one clinical trial, NCT00000280, titled "Glutaminergic Agents for Cocaine Abuse - 5." This Phase 1 study in the United States enrolled adults aged 18 years and older with cocaine-related disorders. The trial is completed, was uncontrolled, and did not use randomization or blinding.
Nimodipine is a small molecule drug being investigated for cocaine-related disorders. No alternative names have been reported for this drug in its clinical development. It is being studied under the name Nimodipine by National Healthcare Corp. in a Phase 1 trial.